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Abstract Fanconi anemia (FA) is a fatal inherited disease
displaying chromosomal instability, disturbances in oxygen
metabolism and a high burden of intracellular radical oxygen
species. Oxygen radicals can damage DNA including telomeric
regions. Insufficient repair results in single strand breaks that
can induce accelerated telomere shortening. In a longitudinal
study we demonstrate that telomeric DNA is continuously lost at
a higher rate in FA fibroblasts compared to healthy controls.
Furthermore, we show that this loss is caused rather by an
increased shortening per cell division in regularly replicating cells
than by apoptosis. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Fanconi anemia (FA) is an autosomal recessive disease of
childhood that typically leads to death as a result of progres-
sive hypoplastic pancytopenia and bone marrow failure. Ab-
normalities of the skeleton and of inner organs, and an in-
creased risk of developing cancer are additional features of
this disease [1]. The most prominent cellular aberration is a
spontaneous chromosomal instability that is augmented by
the use of alkylating crosslinkers such as mitomycin C, di-
epoxybutane [2] and reactive oxygen species (ROS) [3,4]. A
characteristic cell cycle delay in G2 [5] serves as a further
diagnostic tool.
FA comprises at least seven complementation groups, A^G
[6]. While all FA genes except FANCB and a subgroup of
FANCD have been cloned [7^12] only the gene product of
FANCG could be associated with a known protein, XRCC9,
which is thought to participate in DNA repair or control of
the cell cycle checkpoint [9].
The exact molecular defect of FA is not known, though
defective DNA repair and de¢ciencies in the redox cycling
activities have been investigated and reviewed by Pagano
and Korkina [13]. An elevated level of ROS has been mea-
sured in FA cells [3]. ROS can induce lasting damage to te-
lomeres leading to accelerated telomere shortening in replicat-
ing cells [14].
Since aging of cells is thought to be accompanied by short-
ening of telomeres [15] and since aging is accelerated by ROS
[16,17], it was surmised that, if FA is a disorder of ROS
metabolism, telomere shortening should be accelerated in
FA patients. Indeed, it was recently demonstrated [18,19]
that despite a high individual variance, cells from FA patients
have shorter telomeres in peripheral blood mononuclear cells
(PBMC) compared to controls. Moreover, the rate of telo-
mere shortening was claimed to be accelerated in six FA pa-
tients when measured sequentially at two di¡erent ages. It was
suggested that the short telomere length in PBMC might re-
£ect a high turnover of hematopoietic stem and progenitor
cells, necessitated as compensation for an increased rate of
apoptosis and cell cycle delays in FA. Such stress-induced
replication would lead to shorter telomeres even with a con-
stant rate of shortening per cell division [19].
This explanation might be valid for a whole category of
diseases, such as acquired aplastic anemias, in which telomere
shortening could be demonstrated [18]. FA, however, is an
inherited disease characterized by chromosomal instability.
In FA telomere shortening may not only be a disastrous event
in hematopoietic cells accelerating pancytopenia but may also
be the operative defect underlying the disease. Were this to be
the case then, in fact, telomere shortening should be found in
cells other than hematopoietic cells of a¡ected individuals.
The results reported here demonstrate that telomere short-
ening is accelerated in cultured primary FA ¢broblasts when
measured periodically during a long period of their lifespan.
Since neither apoptosis nor cell loss was intensi¢ed, telomere
shortening may be due to oxidatively damaged telomeric
DNA rather than to stress-induced replication.
2. Materials and methods
2.1. Cell lines and culture conditions
Fibroblast cell lines are described in Table 1. Cells were grown in
minimum essential medium (Biochrom, Berlin, Germany) containing
10% fetal calf serum (Greiner, Germany) in air plus 5% CO2 at 37‡C
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and 90% humidity. Cultures were free of mycoplasma. Cells were
passaged at con£uency 1:2. One passage equals one population dou-
bling (PD).
2.2. Telomere length
Samples for telomere length determination were taken every third
to ¢fth PD. Two or three independent cultures were examined for
each cell line. For preparation of highest quality genomic DNA, cells
at subcon£uency were embedded in 0.65% low-melting agarose plugs
at a density of 106 cells/ml before deproteination by proteinase K
treatment [20,21]. DNA was completely digested by HinfI (60 U per
plug, Boehringer, Mannheim, Germany) at 37‡C. Plugs were analyzed
in a 1% agarose gel by pulsed ¢eld gel electrophoresis (Bio-Rad,
Hercules, CA, USA). Gels were blotted to Hybond N membranes
and hybridized with the telomeric probe (TTAGGG)4, conjugated
directly to alkaline phosphatase (Promega, Madison, WI, USA). A
chemiluminescence signal was recorded on ¢lm within the linear range
and analyzed in an imaging densitometer (Bio-Rad). The average
telomere length was calculated as weighted mean of the optical density
as described [20]. Average telomere shortening rates were calculated
by linear regression.
2.3. Apoptosis
Cells were trypsinized, stained with 2 Wg/ml propidium iodide for
5 min on ice in the dark and the £uorescence in 2U104 cells was
measured in a £ow cytometer (Partec, Mu«nster, Germany) using
blue excitation. Cells showing red propidium iodide £uorescence in-
dicating a damaged plasma membrane were gated out (1^2% of all
cells). Apoptotic cells were de¢ned by their lower forward and higher
sideward scatter intensity [22].
2.4. Growth rate
The PD time was estimated for all cells listed in Table 1 by at least
three independent experiments per cell line as described by Weirich-
Schwaiger et al. [23]. Essentially, cells were seeded on slides. Cytoki-
nesis was blocked by cytochalasin and after 48 h nuclei were stained.
A thousand cells were scored for mono- and binucleate cells and the
relation taken as an indicator of cell cycle duration. In addition, when
cells were cultivated, days between splitting of con£uent cultures at a
1:2 ratio and reach of con£uency were recorded as one PD.
2.5. TRAP assay
For the telomerase measurements the semiquantitative telomere re-
peat ampli¢cation protocol (TRAP) (Intergen) was used. Lysates
equivalent to 2000 cells were analyzed in a telomerase reaction for
20 min, followed by 27 PCR cycles (30 s at 95‡C, 45 s at 60‡C). Gels
were scanned in a phosphorimager (Bio-Rad).
3. Results
For the longitudinal study of telomere length in primary
¢broblasts, control cells were grown under basal culture con-
ditions for up to 50 PDs, FA ¢broblasts for about 40 PDs.
Telomere shortening was measured by Southern blotting at
every third to ¢fth PD.
In Fig. 1A regression curves demonstrate the decline of
telomere lengths in cells of two controls and two representa-
tive FA strains. Fig. 1B gives the average telomere loss in bp
per PD including standard deviation for the controls and four
FA ¢broblast lines. In both graphs the accelerated shortening
of telomeres in FA ¢broblasts is noted.
In order to test whether this phenomenon might be due to
an increased rate of apoptosis in FA ¢broblasts leading in
turn to an increased rate of replication in the remaining cells,
Table 1
Cell lines
Cell line Race, sex, age Phenotype Origin
FLB Caucasian female, 13 years FANCG M. Hirsch-Kau¡mann, Innsbruck, Austria
GM1309 Black male, 12 years FANCA Human Genetic Mutant Cell Repository, Camden, NJ, USA
1424 Caucasian male, 10 years FANCG K. Sperling, Berlin, Germany
F71 Arabian male, 14 years FANCA? R. Voss, Israel
GM368 Black male, 8 years FANC Human Genetic Mutant Cell Repository, Camden, NJ, USA
FISG Caucasian male, 1 year FANC M. Hirsch-Kau¡mann, Innsbruck, Austria
KoHe Caucasian male, 25 years control M. Hirsch-Kau¡mann, Innsbruck, Austria
KoDo Caucasian male, 28 years control M. Hirsch-Kau¡mann, Innsbruck, Austria
KoHi Caucasian female, 38 years control M. Hirsch-Kau¡mann, Innsbruck, Austria
KoKr Caucasian male, 28 years control M. Hirsch-Kau¡mann, Innsbruck, Austria
Fig. 1. Telomere shortening in FA and control ¢broblasts. A: Aver-
age telomere length T (in bp) vs. PD for two FA ¢broblast lines
(top) and two control lines (bottom). Regression slopes are F71:
359 bp/PD, GM1309: 3127 bp/PD, KoDo: 322 bp/PD, KoHe:
331 bp/PD. B: Mean telomere shortening (vT) in bp/PD in FA
and control ¢broblasts. The telomere shortening was measured in
F71, 1424, FLB and GM1309 and in controls. There is a signi¢cant
di¡erence between the FA group and the control group with
P6 0.05.
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we measured the fraction of apoptotic cells in two of the FA
strains and in one control strain (Fig. 2). No signi¢cant in-
crease in the fraction of the apoptotic cells could be detected
in any of the cells. This result could be con¢rmed by cell
counting (data not shown).
With respect to the growth rate of the cells, FA cells tend to
grow more slowly than ¢broblast lines derived from healthy
control individuals. Throughout the entire observation period
growth was linear and the growth rate was estimated by linear
regression (Fig. 3). Interestingly enough there was no evidence
for an increased drop-out of FA cells from the cycling cells
that would lead to forced replication and telomere loss in the
remaining fraction as measured by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide test and in the trypan
blue assay (data not shown).
In FA PBMC, a higher telomerase activity than in control
PBMC has been found [19]. Normal human ¢broblasts are
devoid of telomerase. In order to ensure that telomere short-
ening in FA ¢broblasts is not modi¢ed by telomerase, we
measured its activity using the TRAP assay (Fig. 4). Telomer-
ase activity was not measurable in the four FA strains tested.
That this negative result might have occurred due to the pres-
ence of a PCR inhibitor could not be con¢rmed by mixing
experiments with ¢broblasts expressing exogenous telomerase
(Fig. 4, lanes 7 and 8).
4. Discussion
Our data show for the ¢rst time that FA ¢broblast telo-
meres shorten faster than control ¢broblast telomeres during
in vitro growth. Since ¢broblasts in culture recapitulate the
lifespan of the individual from whom they were extracted
[24,23] they are most suitable for a longitudinal study of te-
lomere shortening. Without a corresponding change in the
amount of telomere shortening per cell division, the acceler-
ated rate of telomere shortening in FA PBMC might be as-
cribed to cell loss and cycle exit alone [19]. However, cultures
of ¢broblasts show no indication for further accelerated cell
loss, neither was the rate of apoptosis increased nor was other
evidence of cell decay observable.
The slower growth of FA ¢broblasts compared to their
normal counterparts (Fig. 3) is probably the result of sponta-
neous chromosomal breaks inducing a G2 delay [25,26]. Te-
lomere loss in turn signals cell cycle arrest and chromosomal
Fig. 2. Apoptosis in FA and control ¢broblasts. Forward/sideward
(FSC/SSC) scattergrams of control cells (KoHe) and two di¡erent
FA lines (FLB and GM1309). Apoptotic cells are smaller (lower
FSC) and more granular (higher SSC) than normal cells.
Fig. 3. Growth rate of FA and control ¢broblasts. Growth (in PD)
vs. time (in days) in ¢ve FA lines (b) and four control ¢broblast
lines (8). Values are means of at least three independent experi-
ments at clusters of ¢ve PDs over the entire observation period.
Fig. 4. TRAP assay. The intensity of the ladder pattern in relation
to that of the TSK1 ampli¢cation standard is a semiquantitative in-
dicator of telomerase activity. Lanes 1 and 2: Human BJ6te ¢bro-
blasts overexpressing the hTERT gene resulting in strong telomerase
activity [36]. Lane 3: F71; lane 4: 1424; lane 5: FLB; lane 6:
GM1309; lane 7: F71 mixed 1:1 with BJ6te; lane 8: GM1309
mixed 1:1 with BJ6te; lane 9: intensity standard (R8); lane 10: neg-
ative control.
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instability as has been shown in yeast [27,28]. These ¢ndings
emphasize that the accelerated telomere shortening rate seen
in FA ¢broblasts is not artifactual ^ that is, it does not occur
as a result of cell loss from the cycling pool.
Our data suggest that the faster telomere shortening seen in
FA ¢broblasts re£ects an accelerated telomere loss per cell
division due to the underlying pathology of FA. Telomere
shortening rates in somatic human cells depend on the inter-
action of oxidative stress and antioxidative defence. Increased
oxidative stress accelerates telomere shortening [14,29,30].
Such an imbalance in oxidative metabolism was postulated
for trisomy 21 [31] in which an accelerated telomere short-
ening was found in lymphocytes [32]. The relationship be-
tween oxidative stress and telomere length is most likely a
result of a de¢ciency in telomeric base excision repair [20].
This results in the accumulation of single strand breaks in
telomeres before DNA replication and the transfer of these
breaks into shorter telomeres during replication [21,33].
The ¢broblast cell culture system permitted, for the ¢rst
time, the accelerated rate of telomere shortening in FA cells
to be measured directly by consecutive analysis. Prior to this,
leukocytes could be analyzed only at non-consecutive time
periods. Moreover, in contrast to the analysis of blood cells
drawn from patients (with the inherent time lapse), we were
able to closely observe our cells in culture continuously. No
signi¢cant signs of senescence were seen during the observa-
tion period nor was a substantial cell loss noticeable with
viability assays. Excluding stress replication, the continuous
acceleration of telomere shortening in FA ¢broblasts strength-
ens the arguments discussed above, that factors such as oxi-
dative stress may in£uence the telomere shortening process.
In FA, chromosomal instability and cell cycle delay may
result from a series of events aggravating each other in a vi-
cious circle: elevated ROS damages DNA, the repair of which
may be impaired [34]. The resulting single strand DNA breaks
accelerate telomere loss. The DNA breaks and telomere loss
lead to cell cycle delay. Shortened telomeres with or without
induction of chromosomal aberrations may cause malignancy
and, at a critical length, may lead to cell death and pancyto-
penia [35]. This cascade of events occurring within the hema-
topoietic system may be responsible for the fatal outcome of
this disease.
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